Date: 2016-10-31
Type of information: Nomination
Compound:
Company: BioTime (USA - CA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 31, 2016, BioTime announced that the company has appointed Jim Knight as Senior Vice President, Head of Corporate Development. He reports to Adi Mohanty , Co-Chief Executive Officer. In his new role, Mr. Knight will oversee business development, portfolio strategy and strategic marketing. He brings more than 20 years of experience in creating portfolio value at publicly-traded companies including, Questcor Pharmaceuticals, Inc. and Elan Pharmaceuticals . Most recently, Mr. Knight was the Vice President of Portfolio Strategy at Questcor from 2010 through 2014. Questcor was acquired by Mallinckrodt Pharmaceuticals for $5.6 billion in that year, and Mr. Knight stayed on for a transition and integration period through 2015. Prior to Questcor, Mr. Knight was at Elan Pharmaceuticals from 2001 to 2008, where he led a global strategic marketing team, working closely with collaborators at Biogen Inc. on the successful development and commercialization of Tysabri, a monoclonal antibody. He started his career in the research group at Biogen, before moving to sales and market analysis roles. Mr. Knight has a BS in Biology from the University of Massachusetts, Amherst and an MBA in High Technology from Northeastern University .
Financial terms:
Latest news:
